Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Inactivated Mycoplasma Hyopneumoniae Vaccine market size was valued at US$ 705 million in 2025 and is forecast to a readjusted size of US$ 967 million by 2032 with a CAGR of 4.6% during review period.
Inactivated Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product based on inactivated Mycoplasma hyopneumoniae antigen. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of enzootic pneumonia-related coughing, lung lesions, secondary infections and production performance losses. The product is usually supplied as an injectable emulsion or suspension, covering both monovalent inactivated vaccines and combination inactivated vaccines containing antigens such as porcine circovirus type 2. Key upstream materials include production strains, dedicated culture media, inactivating agents, adjuvants, buffers, stabilizers, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. On an ex-factory basis, global effective capacity of this product category is estimated at around 1.34 billion doses in 2025, with sales volume of approximately 1.083 billion doses and an average ex-factory price of about USD 0.63 per dose. The industry gross margin in 2025 is estimated at roughly 45%–65%, with multinational brands and multivalent vaccines usually at the upper end of the range, and local monovalent or regional products more commonly positioned in the middle to lower part of the range.
The market for inactivated Mycoplasma Hyopneumoniae Vaccine has established a mature application base, with demand mainly supported by the long-term need for integrated respiratory disease control in commercial swine farms. As pig farming continues to move toward larger-scale, more intensive and more standardized management, farms are placing greater emphasis on stable vaccination programs, vaccine safety and herd-level protection. The product is widely used in piglet and nursery-stage immunization and serves not only as a basic preventive vaccine but also as an important management tool to reduce respiratory problems during the growing-finishing stage. Current competition is no longer limited to monovalent vaccine pricing, but is increasingly shaped by product stability, duration of immunity, farm service capability and the value of integrated health solutions.
Looking ahead, combination vaccines and one-shot immunization programs are expected to gain further importance, especially products linked with the prevention needs of porcine circovirus, bacterial respiratory pathogens and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. At the same time, adjuvant systems, antigen purification, strain adaptability and batch-to-batch consistency will become key directions for product upgrading, driving the industry from traditional monovalent vaccine competition toward higher-quality combination vaccines and scenario-based immunization programs.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, its long-term impact on feed conversion, average daily gain, lung lesions and secondary infections can create hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, product consistency and whole-cycle herd health value, rather than purchase price alone.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of combination vaccines may also limit market penetration. Meanwhile, new vaccine routes, differences in local strains, regulatory approval requirements and cold-chain distribution conditions add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
This report is a detailed and comprehensive analysis for global Inactivated Mycoplasma Hyopneumoniae Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Inactivated Mycoplasma Hyopneumoniae Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Inactivated Mycoplasma Hyopneumoniae Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine, with price, sales quantity, revenue, and global market share of Inactivated Mycoplasma Hyopneumoniae Vaccine from 2021 to 2026.
Chapter 3, the Inactivated Mycoplasma Hyopneumoniae Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Mycoplasma Hyopneumoniae Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Inactivated Mycoplasma Hyopneumoniae Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inactivated Mycoplasma Hyopneumoniae Vaccine.
Chapter 14 and 15, to describe Inactivated Mycoplasma Hyopneumoniae Vaccine sales channel, distributors, customers, research findings and conclusion.
Inactivated Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product based on inactivated Mycoplasma hyopneumoniae antigen. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of enzootic pneumonia-related coughing, lung lesions, secondary infections and production performance losses. The product is usually supplied as an injectable emulsion or suspension, covering both monovalent inactivated vaccines and combination inactivated vaccines containing antigens such as porcine circovirus type 2. Key upstream materials include production strains, dedicated culture media, inactivating agents, adjuvants, buffers, stabilizers, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. On an ex-factory basis, global effective capacity of this product category is estimated at around 1.34 billion doses in 2025, with sales volume of approximately 1.083 billion doses and an average ex-factory price of about USD 0.63 per dose. The industry gross margin in 2025 is estimated at roughly 45%–65%, with multinational brands and multivalent vaccines usually at the upper end of the range, and local monovalent or regional products more commonly positioned in the middle to lower part of the range.
The market for inactivated Mycoplasma Hyopneumoniae Vaccine has established a mature application base, with demand mainly supported by the long-term need for integrated respiratory disease control in commercial swine farms. As pig farming continues to move toward larger-scale, more intensive and more standardized management, farms are placing greater emphasis on stable vaccination programs, vaccine safety and herd-level protection. The product is widely used in piglet and nursery-stage immunization and serves not only as a basic preventive vaccine but also as an important management tool to reduce respiratory problems during the growing-finishing stage. Current competition is no longer limited to monovalent vaccine pricing, but is increasingly shaped by product stability, duration of immunity, farm service capability and the value of integrated health solutions.
Looking ahead, combination vaccines and one-shot immunization programs are expected to gain further importance, especially products linked with the prevention needs of porcine circovirus, bacterial respiratory pathogens and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. At the same time, adjuvant systems, antigen purification, strain adaptability and batch-to-batch consistency will become key directions for product upgrading, driving the industry from traditional monovalent vaccine competition toward higher-quality combination vaccines and scenario-based immunization programs.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, its long-term impact on feed conversion, average daily gain, lung lesions and secondary infections can create hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, product consistency and whole-cycle herd health value, rather than purchase price alone.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of combination vaccines may also limit market penetration. Meanwhile, new vaccine routes, differences in local strains, regulatory approval requirements and cold-chain distribution conditions add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
This report is a detailed and comprehensive analysis for global Inactivated Mycoplasma Hyopneumoniae Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Inactivated Mycoplasma Hyopneumoniae Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Inactivated Mycoplasma Hyopneumoniae Vaccine
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Inactivated Mycoplasma Hyopneumoniae Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Single Vaccine
- Dual Vaccine
- Others
- Oil-adjuvanted
- Aqueous-adjuvanted
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20–50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Pig Farming Groups
- Breeding Pig Farms
- Animal Health Service Providers
- Others
- Zoetis
- Boehringer Ingelheim
- Merck Animal Health
- Ceva Sant? Animale
- HIPRA
- Bioveta
- Vaxxinova
- Nisseiken
- Kyoto Biken Laboratories
- Pulike Biological Engineering
- Wuhan Keqian Biology
- Huapai Biotechnology
- TianKang Pharmaceutical
- Qilu Animal Health
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Inactivated Mycoplasma Hyopneumoniae Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine, with price, sales quantity, revenue, and global market share of Inactivated Mycoplasma Hyopneumoniae Vaccine from 2021 to 2026.
Chapter 3, the Inactivated Mycoplasma Hyopneumoniae Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Mycoplasma Hyopneumoniae Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Inactivated Mycoplasma Hyopneumoniae Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inactivated Mycoplasma Hyopneumoniae Vaccine.
Chapter 14 and 15, to describe Inactivated Mycoplasma Hyopneumoniae Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Single Vaccine
1.3.3 Dual Vaccine
1.3.4 Others
1.4 Market Analysis by Adjuvant Type
1.4.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Adjuvant Type: 2021 Versus 2025 Versus 2032
1.4.2 Oil-adjuvanted
1.4.3 Aqueous-adjuvanted
1.4.4 Others
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Pig Farming Groups
1.6.3 Breeding Pig Farms
1.6.4 Animal Health Service Providers
1.6.5 Others
1.7 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size & Forecast
1.7.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (2021-2032)
1.7.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Zoetis
2.1.1 Zoetis Details
2.1.2 Zoetis Major Business
2.1.3 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.1.4 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Zoetis Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.2.4 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Merck Animal Health
2.3.1 Merck Animal Health Details
2.3.2 Merck Animal Health Major Business
2.3.3 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.3.4 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Merck Animal Health Recent Developments/Updates
2.4 Ceva Sant? Animale
2.4.1 Ceva Sant? Animale Details
2.4.2 Ceva Sant? Animale Major Business
2.4.3 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.4.4 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Ceva Sant? Animale Recent Developments/Updates
2.5 HIPRA
2.5.1 HIPRA Details
2.5.2 HIPRA Major Business
2.5.3 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.5.4 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 HIPRA Recent Developments/Updates
2.6 Bioveta
2.6.1 Bioveta Details
2.6.2 Bioveta Major Business
2.6.3 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.6.4 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Bioveta Recent Developments/Updates
2.7 Vaxxinova
2.7.1 Vaxxinova Details
2.7.2 Vaxxinova Major Business
2.7.3 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.7.4 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Vaxxinova Recent Developments/Updates
2.8 Nisseiken
2.8.1 Nisseiken Details
2.8.2 Nisseiken Major Business
2.8.3 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.8.4 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Nisseiken Recent Developments/Updates
2.9 Kyoto Biken Laboratories
2.9.1 Kyoto Biken Laboratories Details
2.9.2 Kyoto Biken Laboratories Major Business
2.9.3 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.9.4 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Kyoto Biken Laboratories Recent Developments/Updates
2.10 Pulike Biological Engineering
2.10.1 Pulike Biological Engineering Details
2.10.2 Pulike Biological Engineering Major Business
2.10.3 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.10.4 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Pulike Biological Engineering Recent Developments/Updates
2.11 Wuhan Keqian Biology
2.11.1 Wuhan Keqian Biology Details
2.11.2 Wuhan Keqian Biology Major Business
2.11.3 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.11.4 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Wuhan Keqian Biology Recent Developments/Updates
2.12 Huapai Biotechnology
2.12.1 Huapai Biotechnology Details
2.12.2 Huapai Biotechnology Major Business
2.12.3 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.12.4 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Huapai Biotechnology Recent Developments/Updates
2.13 TianKang Pharmaceutical
2.13.1 TianKang Pharmaceutical Details
2.13.2 TianKang Pharmaceutical Major Business
2.13.3 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.13.4 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 TianKang Pharmaceutical Recent Developments/Updates
2.14 Qilu Animal Health
2.14.1 Qilu Animal Health Details
2.14.2 Qilu Animal Health Major Business
2.14.3 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.14.4 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Qilu Animal Health Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INACTIVATED MYCOPLASMA HYOPNEUMONIAE VACCINE BY MANUFACTURER
3.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer Market Share in 2025
3.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Overall Company Footprint Analysis
3.5.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Region Footprint
3.5.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
3.5.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Region
4.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2032)
4.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.3 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.5 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2021-2032)
5.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2021-2032)
6.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
7.3.1 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
8.3.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Region
9.3.1 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
10.3.1 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
11.3.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
12.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Restraints
12.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Inactivated Mycoplasma Hyopneumoniae Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Inactivated Mycoplasma Hyopneumoniae Vaccine
13.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
14.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Single Vaccine
1.3.3 Dual Vaccine
1.3.4 Others
1.4 Market Analysis by Adjuvant Type
1.4.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Adjuvant Type: 2021 Versus 2025 Versus 2032
1.4.2 Oil-adjuvanted
1.4.3 Aqueous-adjuvanted
1.4.4 Others
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Pig Farming Groups
1.6.3 Breeding Pig Farms
1.6.4 Animal Health Service Providers
1.6.5 Others
1.7 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size & Forecast
1.7.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (2021-2032)
1.7.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Zoetis
2.1.1 Zoetis Details
2.1.2 Zoetis Major Business
2.1.3 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.1.4 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Zoetis Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.2.4 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Merck Animal Health
2.3.1 Merck Animal Health Details
2.3.2 Merck Animal Health Major Business
2.3.3 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.3.4 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Merck Animal Health Recent Developments/Updates
2.4 Ceva Sant? Animale
2.4.1 Ceva Sant? Animale Details
2.4.2 Ceva Sant? Animale Major Business
2.4.3 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.4.4 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Ceva Sant? Animale Recent Developments/Updates
2.5 HIPRA
2.5.1 HIPRA Details
2.5.2 HIPRA Major Business
2.5.3 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.5.4 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 HIPRA Recent Developments/Updates
2.6 Bioveta
2.6.1 Bioveta Details
2.6.2 Bioveta Major Business
2.6.3 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.6.4 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Bioveta Recent Developments/Updates
2.7 Vaxxinova
2.7.1 Vaxxinova Details
2.7.2 Vaxxinova Major Business
2.7.3 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.7.4 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Vaxxinova Recent Developments/Updates
2.8 Nisseiken
2.8.1 Nisseiken Details
2.8.2 Nisseiken Major Business
2.8.3 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.8.4 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Nisseiken Recent Developments/Updates
2.9 Kyoto Biken Laboratories
2.9.1 Kyoto Biken Laboratories Details
2.9.2 Kyoto Biken Laboratories Major Business
2.9.3 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.9.4 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Kyoto Biken Laboratories Recent Developments/Updates
2.10 Pulike Biological Engineering
2.10.1 Pulike Biological Engineering Details
2.10.2 Pulike Biological Engineering Major Business
2.10.3 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.10.4 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Pulike Biological Engineering Recent Developments/Updates
2.11 Wuhan Keqian Biology
2.11.1 Wuhan Keqian Biology Details
2.11.2 Wuhan Keqian Biology Major Business
2.11.3 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.11.4 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Wuhan Keqian Biology Recent Developments/Updates
2.12 Huapai Biotechnology
2.12.1 Huapai Biotechnology Details
2.12.2 Huapai Biotechnology Major Business
2.12.3 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.12.4 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Huapai Biotechnology Recent Developments/Updates
2.13 TianKang Pharmaceutical
2.13.1 TianKang Pharmaceutical Details
2.13.2 TianKang Pharmaceutical Major Business
2.13.3 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.13.4 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 TianKang Pharmaceutical Recent Developments/Updates
2.14 Qilu Animal Health
2.14.1 Qilu Animal Health Details
2.14.2 Qilu Animal Health Major Business
2.14.3 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
2.14.4 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Qilu Animal Health Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INACTIVATED MYCOPLASMA HYOPNEUMONIAE VACCINE BY MANUFACTURER
3.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer Market Share in 2025
3.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Overall Company Footprint Analysis
3.5.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Region Footprint
3.5.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
3.5.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Region
4.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2032)
4.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.3 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.5 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2021-2032)
5.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2021-2032)
6.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
7.3.1 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
8.3.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Region
9.3.1 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
10.3.1 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country
11.3.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
12.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Market Restraints
12.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Inactivated Mycoplasma Hyopneumoniae Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Inactivated Mycoplasma Hyopneumoniae Vaccine
13.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
14.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Table 3. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Zoetis Basic Information, Manufacturing Base and Competitors
Table 6. Zoetis Major Business
Table 7. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 8. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Zoetis Recent Developments/Updates
Table 10. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 11. Boehringer Ingelheim Major Business
Table 12. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 13. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Boehringer Ingelheim Recent Developments/Updates
Table 15. Merck Animal Health Basic Information, Manufacturing Base and Competitors
Table 16. Merck Animal Health Major Business
Table 17. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 18. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Merck Animal Health Recent Developments/Updates
Table 20. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 21. Ceva Sant? Animale Major Business
Table 22. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 23. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Ceva Sant? Animale Recent Developments/Updates
Table 25. HIPRA Basic Information, Manufacturing Base and Competitors
Table 26. HIPRA Major Business
Table 27. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 28. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. HIPRA Recent Developments/Updates
Table 30. Bioveta Basic Information, Manufacturing Base and Competitors
Table 31. Bioveta Major Business
Table 32. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 33. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Bioveta Recent Developments/Updates
Table 35. Vaxxinova Basic Information, Manufacturing Base and Competitors
Table 36. Vaxxinova Major Business
Table 37. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 38. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Vaxxinova Recent Developments/Updates
Table 40. Nisseiken Basic Information, Manufacturing Base and Competitors
Table 41. Nisseiken Major Business
Table 42. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 43. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Nisseiken Recent Developments/Updates
Table 45. Kyoto Biken Laboratories Basic Information, Manufacturing Base and Competitors
Table 46. Kyoto Biken Laboratories Major Business
Table 47. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 48. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Kyoto Biken Laboratories Recent Developments/Updates
Table 50. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 51. Pulike Biological Engineering Major Business
Table 52. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 53. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Pulike Biological Engineering Recent Developments/Updates
Table 55. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 56. Wuhan Keqian Biology Major Business
Table 57. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 58. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Wuhan Keqian Biology Recent Developments/Updates
Table 60. Huapai Biotechnology Basic Information, Manufacturing Base and Competitors
Table 61. Huapai Biotechnology Major Business
Table 62. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 63. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Huapai Biotechnology Recent Developments/Updates
Table 65. TianKang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. TianKang Pharmaceutical Major Business
Table 67. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 68. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. TianKang Pharmaceutical Recent Developments/Updates
Table 70. Qilu Animal Health Basic Information, Manufacturing Base and Competitors
Table 71. Qilu Animal Health Major Business
Table 72. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 73. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Qilu Animal Health Recent Developments/Updates
Table 75. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 76. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 77. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 78. Market Position of Manufacturers in Inactivated Mycoplasma Hyopneumoniae Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 79. Head Office and Inactivated Mycoplasma Hyopneumoniae Vaccine Production Site of Key Manufacturer
Table 80. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
Table 81. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
Table 82. Inactivated Mycoplasma Hyopneumoniae Vaccine New Market Entrants and Barriers to Market Entry
Table 83. Inactivated Mycoplasma Hyopneumoniae Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 85. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 86. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 87. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 88. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 89. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 90. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 91. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 94. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 95. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 96. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 97. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 98. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 99. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 102. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 103. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 104. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 105. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 106. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 107. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 108. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 109. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 110. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 111. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 112. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 113. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 114. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 115. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 116. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 117. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 118. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 120. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 121. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 122. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 123. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 124. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 125. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 126. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 127. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 128. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 129. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 130. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 131. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 132. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 133. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 134. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 135. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 136. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 137. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 138. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 139. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 140. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 141. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 142. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 143. Inactivated Mycoplasma Hyopneumoniae Vaccine Raw Material
Table 144. Key Manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine Raw Materials
Table 145. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
Table 146. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
Table 1. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Table 3. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Zoetis Basic Information, Manufacturing Base and Competitors
Table 6. Zoetis Major Business
Table 7. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 8. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Zoetis Recent Developments/Updates
Table 10. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 11. Boehringer Ingelheim Major Business
Table 12. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 13. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Boehringer Ingelheim Recent Developments/Updates
Table 15. Merck Animal Health Basic Information, Manufacturing Base and Competitors
Table 16. Merck Animal Health Major Business
Table 17. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 18. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Merck Animal Health Recent Developments/Updates
Table 20. Ceva Sant? Animale Basic Information, Manufacturing Base and Competitors
Table 21. Ceva Sant? Animale Major Business
Table 22. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 23. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Ceva Sant? Animale Recent Developments/Updates
Table 25. HIPRA Basic Information, Manufacturing Base and Competitors
Table 26. HIPRA Major Business
Table 27. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 28. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. HIPRA Recent Developments/Updates
Table 30. Bioveta Basic Information, Manufacturing Base and Competitors
Table 31. Bioveta Major Business
Table 32. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 33. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Bioveta Recent Developments/Updates
Table 35. Vaxxinova Basic Information, Manufacturing Base and Competitors
Table 36. Vaxxinova Major Business
Table 37. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 38. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Vaxxinova Recent Developments/Updates
Table 40. Nisseiken Basic Information, Manufacturing Base and Competitors
Table 41. Nisseiken Major Business
Table 42. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 43. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Nisseiken Recent Developments/Updates
Table 45. Kyoto Biken Laboratories Basic Information, Manufacturing Base and Competitors
Table 46. Kyoto Biken Laboratories Major Business
Table 47. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 48. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Kyoto Biken Laboratories Recent Developments/Updates
Table 50. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 51. Pulike Biological Engineering Major Business
Table 52. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 53. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Pulike Biological Engineering Recent Developments/Updates
Table 55. Wuhan Keqian Biology Basic Information, Manufacturing Base and Competitors
Table 56. Wuhan Keqian Biology Major Business
Table 57. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 58. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Wuhan Keqian Biology Recent Developments/Updates
Table 60. Huapai Biotechnology Basic Information, Manufacturing Base and Competitors
Table 61. Huapai Biotechnology Major Business
Table 62. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 63. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Huapai Biotechnology Recent Developments/Updates
Table 65. TianKang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. TianKang Pharmaceutical Major Business
Table 67. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 68. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. TianKang Pharmaceutical Recent Developments/Updates
Table 70. Qilu Animal Health Basic Information, Manufacturing Base and Competitors
Table 71. Qilu Animal Health Major Business
Table 72. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product and Services
Table 73. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Qilu Animal Health Recent Developments/Updates
Table 75. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 76. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 77. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 78. Market Position of Manufacturers in Inactivated Mycoplasma Hyopneumoniae Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 79. Head Office and Inactivated Mycoplasma Hyopneumoniae Vaccine Production Site of Key Manufacturer
Table 80. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Type Footprint
Table 81. Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Company Product Application Footprint
Table 82. Inactivated Mycoplasma Hyopneumoniae Vaccine New Market Entrants and Barriers to Market Entry
Table 83. Inactivated Mycoplasma Hyopneumoniae Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 85. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 86. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 87. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 88. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 89. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 90. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 91. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 94. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 95. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 96. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 97. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 98. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 99. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 102. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 103. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 104. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 105. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 106. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 107. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 108. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 109. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 110. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 111. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 112. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 113. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 114. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 115. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 116. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 117. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 118. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 120. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 121. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 122. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 123. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 124. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 125. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 126. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 127. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 128. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 129. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 130. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 131. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 132. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 133. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 134. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 135. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 136. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 137. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 138. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 139. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 140. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 141. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 142. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 143. Inactivated Mycoplasma Hyopneumoniae Vaccine Raw Material
Table 144. Key Manufacturers of Inactivated Mycoplasma Hyopneumoniae Vaccine Raw Materials
Table 145. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Distributors
Table 146. Inactivated Mycoplasma Hyopneumoniae Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Inactivated Mycoplasma Hyopneumoniae Vaccine Picture
Figure 2. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type in 2025
Figure 4. Single Vaccine Examples
Figure 5. Dual Vaccine Examples
Figure 6. Others Examples
Figure 7. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Adjuvant Type in 2025
Figure 9. Oil-adjuvanted Examples
Figure 10. Aqueous-adjuvanted Examples
Figure 11. Others Examples
Figure 12. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Pig Farming Groups Examples
Figure 20. Breeding Pig Farms Examples
Figure 21. Animal Health Service Providers Examples
Figure 22. Others Examples
Figure 23. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
Figure 86. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Restraints
Figure 87. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine
Figure 91. Inactivated Mycoplasma Hyopneumoniae Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
Figure 1. Inactivated Mycoplasma Hyopneumoniae Vaccine Picture
Figure 2. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type in 2025
Figure 4. Single Vaccine Examples
Figure 5. Dual Vaccine Examples
Figure 6. Others Examples
Figure 7. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Adjuvant Type, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Adjuvant Type in 2025
Figure 9. Oil-adjuvanted Examples
Figure 10. Aqueous-adjuvanted Examples
Figure 11. Others Examples
Figure 12. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Pig Farming Groups Examples
Figure 20. Breeding Pig Farms Examples
Figure 21. Animal Health Service Providers Examples
Figure 22. Others Examples
Figure 23. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Inactivated Mycoplasma Hyopneumoniae Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Drivers
Figure 86. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Restraints
Figure 87. Inactivated Mycoplasma Hyopneumoniae Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine
Figure 91. Inactivated Mycoplasma Hyopneumoniae Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
